Literature DB >> 30176553

Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy.

Åsa Wickberg1, Anders Magnuson2, Lars Holmberg3, Hans-Olov Adami4, Göran Liljegren5.   

Abstract

PURPOSE: To investigate if intrinsic subtypes of breast cancer predict different risks of ipsilateral breast tumor recurrence (IBTR) following breast-conserving surgery (BCS) with and without postoperative radiation therapy. PATIENTS AND METHODS: We randomized 381 women with a unifocal T1N0M0 breast cancer to BCS alone (197 women) or BCS plus postoperative radiation therapy (XRT) (184 women). All available histopathological material was re-analyzed with modern immunohistochemical methods (223 women). After 20 years of complete follow-up we analyzed the risk of IBTR by intrinsic breast cancer subtypes (luminal A, luminal B/HER2-negative, luminal B/HER2-positive, HER2-positive and triple negative). We used Cox regression analyses to estimate hazard ratios (HR) with 95% confidence intervals (CI).
RESULTS: In a multivariate analysis the luminal B/HER2-negative subtype, compared with the luminal A subtype, was associated with a higher risk of IBTR overall (HR 3.04; 95% CI 1.38-6.71) and in both the XRT-group (HR 5.08 95% CI 1.31-19.7) and the non-XRT-group (HR 2.58 95%CI 1.07-6.20); (p for interaction = 0.37). The risk of IBTR in the XRT- and non-XRT group, stratified by intrinsic subtype, revealed an absolute risk difference at 20 years to the benefit of XRT of 14% (95% CI 1.0%-26%) for luminal A, 17% (95% CI -6.0% to 39%) for luminal B/HER2 negative and 22% (95% CI -7.0-51%) for the high-risk group.
CONCLUSIONS: Among breast cancer patients treated with BCS, the luminal B/HER2-negative subtype predicts an about 3-fold higher risk for IBTR compared to other intrinsic subtypes independent of postoperative radiation therapy.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30176553     DOI: 10.1016/j.breast.2018.08.097

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  3 in total

1.  Nomogram for Predicting Overall Survival and Assessing the Survival Benefit of Adjuvant Treatment in pT1-2N0M0 Triple-Negative Breast Cancer: A Surveillance, Epidemiology, and End Results-Based Study.

Authors:  Qixin Mao; Shanqing Liu; Minhao Lv; Yadong Sun; Chongjian Zhang; Lianfang Li
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

Review 2.  Triple-negative breast cancer and radiation therapy.

Authors:  Jordana de Faria Bessa; Gustavo Nader Marta
Journal:  Rep Pract Oncol Radiother       Date:  2022-07-29

3.  Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.

Authors:  Zhen Zhai; Yi Zheng; Jia Yao; Yu Liu; Jian Ruan; Yujiao Deng; Linghui Zhou; Peng Zhao; Si Yang; Jingjing Hu; Bajin We; Ying Wu; Dai Zhang; Huafeng Kang; Zhijun Dai
Journal:  JAMA Netw Open       Date:  2020-11-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.